Creative Medical Technology Holdings Inc (CELZ)

$2.65 -0.14 (-5.02%)
Market Cap 7.21M
Revenue (ttm) 10,000.00
Net Income (ttm) -5.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -54,900.00%
Debt to Equity Ratio 0.00
Volume 58,600
Avg Vol 54,076
Day's Range N/A - N/A
Shares Out 2.59M
Stochastic %K 69%
Beta 1.98
Analysts Strong Sell
Price Target $20.00

Company Profile

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized super...

Industry: Biotechnology
Sector: Healthcare
Phone: (480) 399-2822
Address:
211 East Osborn Road, Phoenix, United States
Ebrice73
Ebrice73 Jun. 28 at 2:31 AM
$CELZ a lot of action after close here 😄👍
0 · Reply
wokazn
wokazn Jun. 26 at 4:04 PM
$CELZ AlloStem development with Greenstone is going to be huge! This presentation is great! https://youtu.be/bmgIAVGPlH8?si=wATn2Aj01gXA5cTW
1 · Reply
Bobby_J_Bomb
Bobby_J_Bomb Jun. 26 at 10:43 AM
$CELZ getting closer!
0 · Reply
Kjstock
Kjstock Jun. 25 at 4:38 PM
$CELZ Tim came out with his normal fluff on LinkedIn this morning, but it doesn’t really say anything. The good news is that this appears to be in use now which will finally give them a revenue stream. https://stemspine.com/become-a-provider/
1 · Reply
luxm3
luxm3 Jun. 25 at 2:09 PM
$CELZ in....SL 2.37.....1tp 2.9...2tp 3.3......3tp 4.2... just my opinion..
0 · Reply
AZOZ
AZOZ Jun. 25 at 11:38 AM
$CELZ reversal in progress!
1 · Reply
wokazn
wokazn Jun. 23 at 3:50 PM
$CELZ $SANA great achievement in the field for type 1 diabetes!
1 · Reply
wokazn
wokazn Jun. 20 at 3:57 PM
$CELZ 3 years ago...wonder if they have done pilot studies on humans yet!
0 · Reply
jackedmund99
jackedmund99 Jun. 20 at 12:10 PM
$CELZ can anyone confirm the amount of shares outstanding and its present market cap?
1 · Reply
Bobby_J_Bomb
Bobby_J_Bomb Jun. 20 at 11:15 AM
$GLMD $CELZ Low float, cash funded monsters with game changing clinicals. Lets get at it!!!
0 · Reply
Latest News on CELZ
Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain

Mar 20, 2025, 7:50 AM EDT - 3 months ago

Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds

Mar 6, 2025, 8:10 AM EST - 4 months ago

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds

Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™

Feb 14, 2025, 7:00 AM EST - 4 months ago

Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™

Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program

Feb 11, 2025, 9:25 AM EST - 4 months ago

Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program

Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development

Feb 5, 2025, 8:25 AM EST - 5 months ago

Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

Jan 30, 2025, 9:25 AM EST - 5 months ago

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

Top 3 Real Estate Stocks That May Explode In Q4

Nov 25, 2024, 9:03 AM EST - 7 months ago

Top 3 Real Estate Stocks That May Explode In Q4

OPI WHLR

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

Nov 13, 2024, 9:00 AM EST - 8 months ago

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program

Jul 24, 2024, 9:00 AM EDT - 1 year ago

Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program

Creative Medical Technology Holdings Provides Corporate Update

Jul 10, 2024, 8:30 AM EDT - 1 year ago

Creative Medical Technology Holdings Provides Corporate Update

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access

Mar 7, 2024, 9:15 AM EST - 1 year ago

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access

Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy

Mar 6, 2024, 7:00 AM EST - 1 year ago

Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy

Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain

Dec 20, 2023, 9:35 AM EST - 1 year ago

Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain

Oct 10, 2023, 8:00 AM EDT - 1 year ago

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain

Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain

Sep 19, 2023, 8:00 AM EDT - 1 year ago

Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain

What Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth?

Aug 24, 2023, 10:45 AM EDT - 2 years ago

What Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth?

The Immunotherapy Market is Expected to Surpass $351.56 Billion by 2030 - Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is Contributing to this Growth

Jul 14, 2023, 9:00 AM EDT - 2 years ago

The Immunotherapy Market is Expected to Surpass $351.56 Billion by 2030 - Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is Contributing to this Growth

Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update

Jul 13, 2023, 9:00 AM EDT - 2 years ago

Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update

Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements

Jun 28, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements

Creative Medical Technology Announces $2 Million Share Repurchase Program

Jun 12, 2023, 8:01 AM EDT - 2 years ago

Creative Medical Technology Announces $2 Million Share Repurchase Program

Creative Medical Technology Holdings Announces Reverse Stock Split

Jun 9, 2023, 12:30 PM EDT - 2 years ago

Creative Medical Technology Holdings Announces Reverse Stock Split

Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform

May 31, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform

Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development

May 22, 2023, 8:30 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line

May 18, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line

Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study

Apr 12, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study

Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update

Apr 4, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update

Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes

Mar 23, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes

Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform Development

Mar 21, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform Development

Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201

Mar 7, 2023, 8:00 AM EST - 2 years ago

Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201

Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects

Feb 14, 2023, 8:00 AM EST - 2 years ago

Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

Feb 8, 2023, 8:00 AM EST - 2 years ago

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes

Nov 3, 2022, 7:30 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes

Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line

Oct 20, 2022, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study

Sep 26, 2022, 8:00 AM EDT - 2 years ago

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study

Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study

Jul 28, 2022, 7:30 AM EDT - 3 years ago

Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study

Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz® Immunotherapy Platform

Jun 15, 2022, 8:30 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz® Immunotherapy Platform

Creative Medical Technology Announces $17 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 29, 2022, 8:40 AM EDT - 3 years ago

Creative Medical Technology Announces $17 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product

Apr 20, 2022, 8:30 AM EDT - 3 years ago

Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product

Creative Medical Technology to Showcase CaverStem® at American Urological Association Annual Meeting - Largest and Most Prominent Gathering of Urologists in the World

Apr 12, 2022, 8:30 AM EDT - 3 years ago

Creative Medical Technology to Showcase CaverStem® at American Urological Association Annual Meeting - Largest and Most Prominent Gathering of Urologists in the World

Why Creative Medical Technology Shares Are Soaring

Mar 23, 2022, 10:15 AM EDT - 3 years ago

Why Creative Medical Technology Shares Are Soaring

Creative Medical Shares Soar On Positive Data from StemSpine Pilot Study

Mar 23, 2022, 10:15 AM EDT - 3 years ago

Creative Medical Shares Soar On Positive Data from StemSpine Pilot Study

Creative Medical Technology Announces Positive Top-Line Results for StemSpine® Pilot Study

Mar 23, 2022, 8:30 AM EDT - 3 years ago

Creative Medical Technology Announces Positive Top-Line Results for StemSpine® Pilot Study

Creative Medical Technology to Participate in the 34th Annual Roth Conference

Mar 8, 2022, 8:30 AM EST - 3 years ago

Creative Medical Technology to Participate in the 34th Annual Roth Conference

Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

Mar 2, 2022, 8:30 AM EST - 3 years ago

Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

Creative Medical Technology Holdings, Inc. Prices $16 Million Public Offering and Uplisting to the Nasdaq Capital Market

Dec 3, 2021, 4:00 AM EST - 3 years ago

Creative Medical Technology Holdings, Inc. Prices $16 Million Public Offering and Uplisting to the Nasdaq Capital Market

Creative Medical Technology Holdings Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to The Nasdaq Capital Market

Nov 9, 2021, 4:45 PM EST - 3 years ago

Creative Medical Technology Holdings Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to The Nasdaq Capital Market

Ebrice73
Ebrice73 Jun. 28 at 2:31 AM
$CELZ a lot of action after close here 😄👍
0 · Reply
wokazn
wokazn Jun. 26 at 4:04 PM
$CELZ AlloStem development with Greenstone is going to be huge! This presentation is great! https://youtu.be/bmgIAVGPlH8?si=wATn2Aj01gXA5cTW
1 · Reply
Bobby_J_Bomb
Bobby_J_Bomb Jun. 26 at 10:43 AM
$CELZ getting closer!
0 · Reply
Kjstock
Kjstock Jun. 25 at 4:38 PM
$CELZ Tim came out with his normal fluff on LinkedIn this morning, but it doesn’t really say anything. The good news is that this appears to be in use now which will finally give them a revenue stream. https://stemspine.com/become-a-provider/
1 · Reply
luxm3
luxm3 Jun. 25 at 2:09 PM
$CELZ in....SL 2.37.....1tp 2.9...2tp 3.3......3tp 4.2... just my opinion..
0 · Reply
AZOZ
AZOZ Jun. 25 at 11:38 AM
$CELZ reversal in progress!
1 · Reply
wokazn
wokazn Jun. 23 at 3:50 PM
$CELZ $SANA great achievement in the field for type 1 diabetes!
1 · Reply
wokazn
wokazn Jun. 20 at 3:57 PM
$CELZ 3 years ago...wonder if they have done pilot studies on humans yet!
0 · Reply
jackedmund99
jackedmund99 Jun. 20 at 12:10 PM
$CELZ can anyone confirm the amount of shares outstanding and its present market cap?
1 · Reply
Bobby_J_Bomb
Bobby_J_Bomb Jun. 20 at 11:15 AM
$GLMD $CELZ Low float, cash funded monsters with game changing clinicals. Lets get at it!!!
0 · Reply
Bobby_J_Bomb
Bobby_J_Bomb Jun. 20 at 11:13 AM
$GLMD $CELZ Yes sir!! Lets rock these low float, cash funded monsters!!! https://stocktwits.com/Bobby_J_Bomb/message/617564869
0 · Reply
Bobby_J_Bomb
Bobby_J_Bomb Jun. 19 at 4:15 PM
$CELZ Indeed!!
0 · Reply
ka1954
ka1954 Jun. 18 at 6:56 PM
$CELZ what else could be expected
1 · Reply
ka1954
ka1954 Jun. 18 at 4:48 PM
$CELZ this will be back to 2.30 tomorrow. this stock never holds its gains. we need news now no matter even small news
0 · Reply
Bobby_J_Bomb
Bobby_J_Bomb Jun. 18 at 3:32 PM
$CELZ My hope would be that they get government grant funding for Phase 3, since it directly aligns with the current administration and HHS secretary goals to get away from opioids and addictive treatments that cause just as much, if not more, harm than they eliminate. If they secure funding with good results, this is $10+.
1 · Reply
The1Albatross
The1Albatross Jun. 17 at 4:59 PM
$CELZ This one bullish Deets soon
1 · Reply
AZOZ
AZOZ Jun. 16 at 3:34 PM
$CELZ close to support 👀
0 · Reply
ka1954
ka1954 Jun. 11 at 7:56 PM
$CELZ took 2 weeks to go up and undone in 1 day. people stop selling for 5 cents
1 · Reply
Bobby_J_Bomb
Bobby_J_Bomb Jun. 11 at 7:17 PM
$CELZ Should be releasing the second cohort of CELZ-201 DDT very soon for lower back pain, including for degenerative disc disease. The addressable market is one of the largest in the world. IF the results are great, which they should be, this will be heading to Phase 3 for a treatment that gets away from opioids and other addictive drugs with major side effects, all with much better efficacy and RFK is HHS Chief and a huge advocate for non-opiod treatments. Could be like $VTGN in 2023 when they released their first positive Phase 3 data for non-SSRI treatment for SAD and other anxiety disorders.
2 · Reply
Bobby_J_Bomb
Bobby_J_Bomb Jun. 11 at 4:04 PM
$GLMD $CELZ looking solid after consolidation. Waiting for a PR to send these!!!
0 · Reply
BoilermakerB
BoilermakerB Jun. 10 at 10:52 AM
$CELZ lets go Tim, drop the PR, then dilitue us and then RS us......thats what you do..... Or maybe actually launch a product instead of just trial after trial.... Revenue and profit reward shareholders
1 · Reply
Bobby_J_Bomb
Bobby_J_Bomb Jun. 9 at 10:10 PM
$CELZ breakout setup. $4+ by end of June.
0 · Reply